会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
    • 给予/给予抗RSV抗体进行预防和治疗的方法
    • US20050147616A1
    • 2005-07-07
    • US10962285
    • 2004-10-08
    • James YoungScott KoenigLeslie JohnsonWilliam HuseJeffrey WatkinsHerren Wu
    • James YoungScott KoenigLeslie JohnsonWilliam HuseJeffrey WatkinsHerren Wu
    • C07K16/10C12P21/08A61K39/42C07H21/04C07K16/08C12N5/06C12Q1/70
    • C07K16/1027A61K2039/505C07K2317/24C07K2317/56C07K2317/565
    • The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection
    • 本发明包括免疫特异性结合一种或多种RSV抗原的新型抗体及其片段,以及包含所述抗体和抗体片段的组合物。 本发明包括预防人类呼吸道合胞病毒(RSV)感染的方法,包括向所述人施用预防有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段,其中一定的血清滴度为 所述抗体或抗体片段在所述人受试者中实现。 本发明还包括用于治疗或改善与人类RSV感染有关的症状的方法,包括向所述人施用治疗有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段,其中一定 所述抗体或抗体片段的血清滴度在所述人受试者中实现。 本发明还包括包含免疫特异性结合RSV抗原的抗体或其片段的组合物,以及使用所述组合物检测或诊断RSV感染的方法
    • 5. 发明申请
    • Heteromeric variable regions with unvaried human framework regions
    • US20050064438A1
    • 2005-03-24
    • US10697400
    • 2003-10-30
    • William HuseJeffry WatkinsHerren Wu
    • William HuseJeffry WatkinsHerren Wu
    • C07K16/28C07K16/36C07K16/46C12Q1/68G01N33/48G01N33/50G06F19/00
    • C07K16/465C07K16/00C07K16/2878C07K16/36C07K16/464C07K2317/24C07K2317/55C07K2317/56C07K2317/92
    • The invention provides a method of conferring donor CDR binding affinity onto an antibody acceptor variable region framework. The method consists of: (a) constructing a population of altered antibody variable region encoding nucleic acids, said population comprising encoding nucleic acids for an acceptor variable region framework containing a plurality of different amino acids at one or more acceptor framework region amino acid positions and donor CDRs containing a plurality of different amino acids at one or more donor CDR amino acid positions; (b) expressing said population of altered variable region encoding nucleic acids, and (c) identifying one or more altered variable regions having binding affinity substantially the same or greater than the donor CDR variable region. The acceptor variable region framework can be a heavy or light chain variable region framework and the populations of heavy and light chain altered variable regions can be expressed alone to identify heavy or light chains having binding affinity substantially the same or greater than the donor CDR variable region. The populations of heavy and light chains additionally can be coexpressed to identify heteromeric altered variable region binding fragments. The invention also provides a method of simultaneously grafting and optimizing the binding affinity of a variable region binding fragment. The method consists of: (a) constructing a population of altered heavy chain variable region encoding nucleic acids comprising an acceptor variable region framework containing donor CDRs and a plurality of different amino acids at one or more framework region and CDR amino acid positions; (b) constructing a population of altered light chain variable region encoding nucleic acids comprising an acceptor variable region framework containing donor CDRs and a plurality of different amino acids at one or more framework regions and CDR amino acid positions; (c) coexpressing said populations of heavy and light chain variable region encoding nucleic acids to produce diverse combinations of heteromeric variable region binding fragments, and (d) identifying one or more heteromeric variable region binding fragments having affinity substantially the same or greater than the donor CDR heteromeric variable region binding fragment. A method of optimizing the binding affinity of an antibody variable region is also provided. The method consists of: (a) constructing a population of antibody variable region encoding nucleic acids, said population comprising two or more CDRs containing a plurality of different amino acids at one or more CDR amino acid positions; (b) expressing said population of variable region encoding nucleic acids, and (c) identifying one or more variable regions having binding affinity substantially the same or greater than the donor CDR variable region. The variable region populations can be heavy or light chains and can be expressed as individual populations or they can be coexpressed to produce heteromeric variable region binding fragments.
    • 7. 发明授权
    • DNA cloning vectors with in vivo excisable plasmids
    • 具有体内可切除质粒的DNA克隆载体
    • US5128256A
    • 1992-07-07
    • US341261
    • 1989-04-20
    • William HuseJoseph A. SorgeJay M. Short
    • William HuseJoseph A. SorgeJay M. Short
    • C12N15/64C12N15/70
    • C12N15/70C12N15/64
    • Vectors are described that circumvent traditional DNA cloning and subcloning procedures, and that contain a unique DNA cartridge that permits both cloning of DNA directly into DNA sequences present within the cartridge, and in vivo removal and circularization of the cartridge thereby yielding an autonomously replicating structure. Because the DNA cartridge can include a wide variety of functional DNA sequences, the cloned DNA can be subjected to a plethora of molecular biological procedures without having to remove the cloned DNA from the cartridge thereby obviating the need to perform additional subcloning techniques. A particularly useful example of this type of vector is bacteriophage lambda containing the DNA cartridge.
    • 描述了可以克服传统DNA克隆和亚克隆程序的载体,并且其含有独特的DNA柱,其允许将DNA直接克隆到存在于盒内的DNA序列中,并且在体内移除和环化圆筒,从而产生自主复制的结构。 因为DNA盒可以包括多种功能性DNA序列,所以克隆的DNA可以经受大量的分子生物学过程,而不必从盒中除去克隆的DNA,从而避免进行附加亚克隆技术的需要。 这种载体的特别有用的实例是含有DNA盒的噬菌体λ。